Epidemiology and treatment of hepatitis C genotypes 5 and 6

Khalid Al Naamani, Siham Al Sinani, Marc Deschen̂es

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Chronic hepatitis C infection is a major global health problem. The WHO estimates the number of infected people worldwide to be approximately 170 million. The estimated number of hepatitis C virus (HCV)-infected people in Canada is approximately 250,000, with approximately 5000 Canadians newly infected each year. Based on the identification of genomic differences, HCV has been classified into six genotypes; genotype may influence the outcome of antiviral therapy. HCV genotypes 1, 2 and 3 are widely distributed throughout the world and have been the focus of the majority of epidemiological, natural course and treatment studies. Although HCV genotypes 5 and 6 are prevalent in certain geographical areas, they are studied less extensively. HCV genotypes 5 and 6 are uncommon in Canada and account for less than 5% of HCV-infected Canadians. However, immigration and travel can alter the epidemiology of these uncommon genotypes. The present article reviews and summarizes the available data regarding the epidemiology and treatment of HCV genotypes 5 and 6. Genotype 5 is endemic in the northern part of South Africa while genotype 6 is reported primarily in Asia. Available data show that 48 weeks of treatment with a combination of pegylated interferon and ribavirin lead to a higher sustained virological response compared with HCV genotypes 1 and 4. None of the approved direct-acting antiviral agents is currently recommended for the treatment of HCV genotypes 5 or 6.

Original languageEnglish
JournalCanadian Journal of Gastroenterology
Volume27
Issue number1
Publication statusPublished - Jan 2013

Fingerprint

Hepatitis C
Epidemiology
Hepacivirus
Genotype
Canada
Antiviral Agents
Ribavirin
Emigration and Immigration
Chronic Hepatitis C
South Africa
Interferons

Keywords

  • Chronic
  • Genotype
  • Hepatitis C

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Al Naamani, K., Al Sinani, S., & Deschen̂es, M. (2013). Epidemiology and treatment of hepatitis C genotypes 5 and 6. Canadian Journal of Gastroenterology, 27(1).

Epidemiology and treatment of hepatitis C genotypes 5 and 6. / Al Naamani, Khalid; Al Sinani, Siham; Deschen̂es, Marc.

In: Canadian Journal of Gastroenterology, Vol. 27, No. 1, 01.2013.

Research output: Contribution to journalArticle

Al Naamani, K, Al Sinani, S & Deschen̂es, M 2013, 'Epidemiology and treatment of hepatitis C genotypes 5 and 6', Canadian Journal of Gastroenterology, vol. 27, no. 1.
Al Naamani, Khalid ; Al Sinani, Siham ; Deschen̂es, Marc. / Epidemiology and treatment of hepatitis C genotypes 5 and 6. In: Canadian Journal of Gastroenterology. 2013 ; Vol. 27, No. 1.
@article{93710716cb6044639fa452210abc50a3,
title = "Epidemiology and treatment of hepatitis C genotypes 5 and 6",
abstract = "Chronic hepatitis C infection is a major global health problem. The WHO estimates the number of infected people worldwide to be approximately 170 million. The estimated number of hepatitis C virus (HCV)-infected people in Canada is approximately 250,000, with approximately 5000 Canadians newly infected each year. Based on the identification of genomic differences, HCV has been classified into six genotypes; genotype may influence the outcome of antiviral therapy. HCV genotypes 1, 2 and 3 are widely distributed throughout the world and have been the focus of the majority of epidemiological, natural course and treatment studies. Although HCV genotypes 5 and 6 are prevalent in certain geographical areas, they are studied less extensively. HCV genotypes 5 and 6 are uncommon in Canada and account for less than 5{\%} of HCV-infected Canadians. However, immigration and travel can alter the epidemiology of these uncommon genotypes. The present article reviews and summarizes the available data regarding the epidemiology and treatment of HCV genotypes 5 and 6. Genotype 5 is endemic in the northern part of South Africa while genotype 6 is reported primarily in Asia. Available data show that 48 weeks of treatment with a combination of pegylated interferon and ribavirin lead to a higher sustained virological response compared with HCV genotypes 1 and 4. None of the approved direct-acting antiviral agents is currently recommended for the treatment of HCV genotypes 5 or 6.",
keywords = "Chronic, Genotype, Hepatitis C",
author = "{Al Naamani}, Khalid and {Al Sinani}, Siham and Marc Deschen̂es",
year = "2013",
month = "1",
language = "English",
volume = "27",
journal = "Canadian Journal of Gastroenterology and Hepatology",
issn = "2291-2789",
publisher = "Pulsus Group Inc.",
number = "1",

}

TY - JOUR

T1 - Epidemiology and treatment of hepatitis C genotypes 5 and 6

AU - Al Naamani, Khalid

AU - Al Sinani, Siham

AU - Deschen̂es, Marc

PY - 2013/1

Y1 - 2013/1

N2 - Chronic hepatitis C infection is a major global health problem. The WHO estimates the number of infected people worldwide to be approximately 170 million. The estimated number of hepatitis C virus (HCV)-infected people in Canada is approximately 250,000, with approximately 5000 Canadians newly infected each year. Based on the identification of genomic differences, HCV has been classified into six genotypes; genotype may influence the outcome of antiviral therapy. HCV genotypes 1, 2 and 3 are widely distributed throughout the world and have been the focus of the majority of epidemiological, natural course and treatment studies. Although HCV genotypes 5 and 6 are prevalent in certain geographical areas, they are studied less extensively. HCV genotypes 5 and 6 are uncommon in Canada and account for less than 5% of HCV-infected Canadians. However, immigration and travel can alter the epidemiology of these uncommon genotypes. The present article reviews and summarizes the available data regarding the epidemiology and treatment of HCV genotypes 5 and 6. Genotype 5 is endemic in the northern part of South Africa while genotype 6 is reported primarily in Asia. Available data show that 48 weeks of treatment with a combination of pegylated interferon and ribavirin lead to a higher sustained virological response compared with HCV genotypes 1 and 4. None of the approved direct-acting antiviral agents is currently recommended for the treatment of HCV genotypes 5 or 6.

AB - Chronic hepatitis C infection is a major global health problem. The WHO estimates the number of infected people worldwide to be approximately 170 million. The estimated number of hepatitis C virus (HCV)-infected people in Canada is approximately 250,000, with approximately 5000 Canadians newly infected each year. Based on the identification of genomic differences, HCV has been classified into six genotypes; genotype may influence the outcome of antiviral therapy. HCV genotypes 1, 2 and 3 are widely distributed throughout the world and have been the focus of the majority of epidemiological, natural course and treatment studies. Although HCV genotypes 5 and 6 are prevalent in certain geographical areas, they are studied less extensively. HCV genotypes 5 and 6 are uncommon in Canada and account for less than 5% of HCV-infected Canadians. However, immigration and travel can alter the epidemiology of these uncommon genotypes. The present article reviews and summarizes the available data regarding the epidemiology and treatment of HCV genotypes 5 and 6. Genotype 5 is endemic in the northern part of South Africa while genotype 6 is reported primarily in Asia. Available data show that 48 weeks of treatment with a combination of pegylated interferon and ribavirin lead to a higher sustained virological response compared with HCV genotypes 1 and 4. None of the approved direct-acting antiviral agents is currently recommended for the treatment of HCV genotypes 5 or 6.

KW - Chronic

KW - Genotype

KW - Hepatitis C

UR - http://www.scopus.com/inward/record.url?scp=84872586986&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84872586986&partnerID=8YFLogxK

M3 - Article

VL - 27

JO - Canadian Journal of Gastroenterology and Hepatology

JF - Canadian Journal of Gastroenterology and Hepatology

SN - 2291-2789

IS - 1

ER -